The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

The Manufacturers Life Insurance Company lessened its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 59.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,060 shares of the company’s stock after selling 64,742 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Neumora Therapeutics were worth $478,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Swiss National Bank bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $1,168,000. Capital International Investors lifted its position in shares of Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock worth $39,224,000 after buying an additional 3,233,179 shares during the period. Wells Fargo & Company MN lifted its position in shares of Neumora Therapeutics by 23.0% during the 4th quarter. Wells Fargo & Company MN now owns 70,653 shares of the company’s stock worth $749,000 after buying an additional 13,196 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $143,000. Finally, Vanguard Group Inc. lifted its position in shares of Neumora Therapeutics by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock worth $48,466,000 after buying an additional 195,142 shares during the period. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Up 5.1%

Shares of Neumora Therapeutics stock opened at $0.70 on Friday. Neumora Therapeutics, Inc. has a 12 month low of $0.61 and a 12 month high of $17.19. The business has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $4.35. The stock has a market cap of $113.22 million, a PE ratio of -0.37 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). Analysts expect that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. HC Wainwright cut their price objective on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Bank of America restated an “underperform” rating and set a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Stifel Nicolaus lowered Neumora Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $6.00 to $2.00 in a research note on Friday, March 7th. Finally, Guggenheim lowered Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $9.29.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.